

# Delirium, Dementia, or Schizophrenia: A Case Report and Literature Review of New-Onset Psychosis in a Geriatric Patient

Grace L. Johnson BA,<sup>1</sup> Kemuel L. Philbrick MD FACLP,<sup>2</sup> Christopher L. Sola DO FACLP<sup>2</sup>  
<sup>1</sup>Mayo Clinic Alix School of Medicine; <sup>2</sup>Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA

## BACKGROUND

- In 2000, an international consensus statement proposed a distinction between early-onset schizophrenia (EOS) and schizophrenia that presents after age 40.<sup>2</sup>
- Very late-onset schizophrenia-like psychosis (VLOSLP) denotes first-break primary psychosis in patients >60 years old.
- We describe an elderly patient with no known psychiatric history who presented with acute psychosis that resolved with high-dose olanzapine, prompting consideration of an undiagnosed primary psychotic disorder.
- We also present a systematic review of VLOSLP case reports.

## CASE REPORT

- History of Present Illness
  - 75-year-old woman admitted to internal medicine for altered mental status after being found huddled outdoors in freezing temperatures.
  - No known past medical or psychiatric history.
  - Medical Work-Up
    - Head/brain CT/MRI: Mild parenchymal volume loss and scattered leukoariosis
    - EEG: Mild diffuse slowing and periodic discharges with triphasic morphology
    - CSF: Aβ42 = 886 (low), total tau = 104 (normal)
    - Remainder of work-up (blood, urine, infectious studies) unremarkable
- Initial Psychiatric Consultation
  - Mental Status Exam: Affective energy, overt confusion, auditory and visual perturbations, paranoia, gross thought disorganization, and consistent attentiveness without waxing/waning
  - Initial recommendations: olanzapine 5 mg q.h.s. ± 2.5 mg b.i.d. p.r.n.
- Follow-Up
  - No improvement initially. Patient experienced insomnia and stopped eating.
  - Olanzapine gradually titrated to 20 mg daily.
  - Psychosis significantly improved one week later. Patient discharged to home.

## LITERATURE REVIEW

- Total: 7 studies, 9 cases
- Age (years, mean ± SD): 72.6 ± 7.7
- Female: 8/9 (89%)
- Persecutory delusions: 8/9 (89%)
- Hallucinations: 7/9 (78%)
- Negative symptoms: 2/9 (22%)
- No patients had a prior psychiatric history.
- MMSE within normal limits for 6/6 patients.
- Treatment: Predominately second-generation antipsychotics ± neuromodulation in 2 cases.
- Response: All patients exhibited significant improvement in psychosis following treatment.

Figure 1. Flow Chart




TABLE 1: Characteristics of the Included Cases

Year	First Author	Age/Sex	Delusions	Hallucinations	Negative Symptoms	Other	Treatment
2023	Regala	64/F	Persecutory	Multimodal	N/A	N/A	Clozapine, aripiprazole, amisulpride
2022	Satake	74/F	N/A	Auditory	Avolition, asociality	MMSE 28/30	Risperidone, quetiapine, aripiprazole, blonanserin, asenapine, paliperidone, ECT
2021	Satake	68/F	Persecutory	Visual	N/A	Anxiety, MMSE 28/30	N/A
		81/F	Persecutory	N/A	N/A	Amnesia, MMSE 28/30	Quetiapine
2021	Melo	80/F	Persecutory	Auditory, visceral	N/A	MMSE WNL	Risperidone
2020	Zollner	66/M	Persecutory	Auditory, tactile	N/A	N/A	Olanzapine, TBS
2014	Sharma	72/F	Persecutory	Auditory	N/A	Insomnia, MMSE 28/30	Risperidone
		84/F	Persecutory	Auditory	N/A	MMSE 30/30	Risperidone
2011	Tsujino	64/F	Persecutory	N/A	Catatonia	N/A	Haloperidol, lorazepam, aripiprazole

## DISCUSSION

- VLOSLP differs from EOS in prevalence, demographic characteristics, and clinical presentation.<sup>1,3</sup>
- Differential diagnosis may include delirium and/or neurodegenerative disease.
- Notable distinctions include preserved cognitive function, absence of waxing/waning attention, and positive response to neuroleptics.

TABLE 2: Distinctions between EOS and VLOSLP

	EOS	VLOSLP
<b>Incidence among patients with schizophrenia</b>	80%	2%
<b>Demographic characteristics</b>	Male predominance	Female predominance
	Strong family history	Weaker family history
	Low post-secondary education completion	Higher post-secondary education completion
	High rates of substance use	Low rates of substance use
	Low premorbid psychosocial functioning	Higher premorbid psychosocial functioning, but Cluster A personality traits are often present
<b>Clinical presentation</b>	Presence of both positive and negative symptoms	Positive symptoms predominate (particularly paranoia, persecutory delusions, and multimodal hallucinations). Negative symptoms are rare.
	Significant cognitive deficits	Milder cognitive deficits

## REFERENCES

- Abou Kassm S, Limosin F, Naja W, Vandell P, Sánchez-Rico M, Alvarado JM, von Gunten A, Hoertel N; CSA Study group. Late-onset and nonlate-onset schizophrenia: A comparison of clinical characteristics in a multicenter study. *Int J Geriatr Psychiatry* 2021 Aug;36(8):1204-1215. DOI: 10.1002/gps.5512
- Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. The International Late-Onset Schizophrenia Group. *Am J Psychiatry* 2000 Feb;157(2):172-178. DOI: 10.1176/appi.ajp.157.2.172
- Suen YN, Wong SMY, Hui CLM, Chan SKW, Lee EHM, Chang WC, Chen EYH. Late-onset psychosis and very-late-onset-schizophrenia-like-psychosis: an updated systematic review. *Int Rev Psychiatry* 2019 Aug-Sep;31(5-6):523-542. DOI: 10.1080/09540261.2019.1670624

## DISCLOSURES

All authors have no funding nor potential conflicts of interest to report.